Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Clinical trial NCT07016399 · RECRUITING

Trial details

NCT number: NCT07016399
Sponsor: Vandana Abramson
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Triple-Negative Breast Carcinoma

Start date: 2025-09-09
Primary completion: 2028-09-01
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.